Comparative Pharmacology
Head-to-head clinical analysis: ATORVALIQ versus LOVASTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVALIQ versus LOVASTATIN.
ATORVALIQ vs LOVASTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATORVALIQ is a combination of atorvastatin and amlodipine. Atorvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Amlodipine is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
10-80 mg orally once daily. Starting dose 10-20 mg. Max dose 80 mg.
10-80 mg orally once daily in the evening, starting at 10-20 mg once daily; maximum dose 80 mg/day.
None Documented
None Documented
Clinical Note
moderateLovastatin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Norfloxacin
"The serum concentration of Norfloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Resveratrol
"The serum concentration of Resveratrol can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Betamethasone
The terminal elimination half-life of atorvastatin is approximately 14 hours; however, its active metabolites have a half-life of 20-30 hours, allowing for once-daily dosing.
Terminal elimination half-life: 1.5–2 hours for lovastatin acid; clinical context: short half-life supports evening dosing to maximize HMG-CoA reductase inhibition during peak cholesterol synthesis.
Atorvastatin is primarily eliminated via biliary/fecal excretion (approximately 70% as metabolites), with renal excretion accounting for less than 2% of the administered dose.
Renal: 10% (as metabolites); Fecal: 83% (primarily as metabolites); Biliary: minor; <5% excreted unchanged in urine.
Category C
Category D/X
Statin
Statin
"The serum concentration of Betamethasone can be increased when it is combined with Lovastatin."